Neal J. Meropol

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens et al. · Journal of Clinical Oncology · 2010 · 557 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers

Andrew L. Pecora, Naiyer A. Rizvi, Gary I. Cohen et al. · Journal of Clinical Oncology · 2002 · 389 citations

Pharmacy, Oncology, Pharmacology +9

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Anthony W. Tolcher, Monica Mita, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 311 citations · Full text

Medicine, Oncology, Pharmacology +17

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Leslie E. Carlini, Neal J. Meropol, John L. Bever et al. · Clinical Cancer Research · 2005 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.

Margaret von Mehren, Philip M. Arlen, Kwong Y. Tsang et al. · PubMed · 2000 · 156 citations

Medicine, Immunology, Oncology +17